:

CEREBRAS TARGETS $40B VALUATION IN NASDAQ IPO

INDUSTRY DESK2 MIN READ
MON, MAY 4, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

AI chip maker Cerebras Systems is going public on Nasdaq under ticker CBRS, with an IPO roadshow beginning Monday and share prices targeted between $115 and $125.

Cerebras Systems, a developer of specialized AI processors, is making a second attempt at a public listing after withdrawing a previous IPO filing. The company aims for a $40 billion valuation, according to sources cited by Reuters. The IPO roadshow launches Monday, with the company targeting a price range of $115 to $125 per share. Trading will occur on the Nasdaq exchange under the ticker symbol CBRS. Cerebras has built its business around custom AI chips designed to accelerate machine learning workloads. The company competes in a crowded field of chip makers targeting the rapidly growing artificial intelligence market, where demand for specialized processors has surged. This represents the company's second effort to reach the public markets. Cerebras previously withdrew an IPO filing, making this renewed push significant for the company's growth plans and ability to raise capital. The timing coincides with investor appetite for AI-focused companies. Major semiconductor firms and AI accelerator makers have seen elevated valuations as enterprises invest heavily in AI infrastructure and capabilities. Celebras' path to the public markets reflects broader trends in the tech industry, where specialized chip designers are increasingly viewed as critical infrastructure plays in the AI era. The company's valuation target places it among significant players in the semiconductor space. The IPO filing comes as the chip market continues to tighten, with competition intensifying among companies offering custom silicon for machine learning applications. Success in the public markets would validate Cerebras' technology and business model while providing resources for product development and market expansion.

■ SOURCES

The Decoder

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

Triomics, an AI platform automating data-heavy tasks for oncologists, secured $22M in Series B funding. The raise follows a $15M Series A in 2024.

12H AGOAI Desk

Xcena secured $135 million in Series B funding at a $570 million valuation for its MX1 chip, which handles data orchestration and KV cache management directly within memory modules.

12H AGOAI Desk

Pittsburgh-based Gray Swan, which stress-tests AI models for frontier labs, secured $40M in Series A funding at a $200M valuation. The round was co-led by Wing VC and Madrona.

20H AGOAI Desk

H1, a healthcare SaaS startup, secured $40 million in funding from CVS Health. The investment signals continued investor confidence in specialized software platforms despite AI disruption concerns.

YESTERDAYIndustry Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.